

Statement on behalf of the Board

Net assets per share were 95p at 31 August 2007, which compares to 86p at 28 February 2007, and 98p at 31 August 2006.

Details of all investees are given in the newsletter, which is available on www.oxfordtechnology.com. While some investees have experienced problems, others are continuing to make encouraging progress. In particular, Glide Pharma has continued to make excellent progress and, in summer 2007, won the Medical Futures Award, the 'Oscars' of its industry.

On behalf of the Board
John Jackson
Chairman

Unaudited Financial Information

Summarised Statement of Total Return for the Period

	Six months to 31 Aug 07 £'000	Six months to 31 Aug 06 £'000	Year to 28 Feb 07 £'000
Gain/(loss) on investments	544	381	(184)
Income	1	6	9
Expenses	(77)	(78)	(161)
Net return before taxation	468	309	(336)
Tax on ordinary activities	-	-	-
Return attributable to equity shareholders	468	309	(336)
Dividends in respect of equity shares	-	-	-
Transfers to reserves	468	309	(336)
Revenue loss per share	(1.40)p	(1.33)p	(2.81)p
Capital return per share	10.06p	7.05p	(3.40)p
Total return per ordinary share	8.66p	5.72p	(6.21)p

Summarised Balance Sheet

	31 Aug 07 £'000	31 Aug 06 £'000	28 Feb 07 £'000
Investments held at fair value	5,169	5,188	4,613
Other net current assets	(43)	115	45
Net assets	5,126	5,303	4,658
Capital and Reserves			
Called up share capital	541	541	541
Share premium: Share issues	4,900	4,900	4,900
Expenses on share issues	(242)	(242)	(242)
Capital reserve - realised	5,199	5,199	5,199
unrealised	(44)	(4)	(44)
Revenue reserve	516	497	(28)
Shareholders' funds	(545)	(389)	(469)
Net asset value per share	95p	98p	86p

Cash Flow Statement for the Period

	Six months to 31 Aug 07 £'000	Six months to 31 Aug 06 £'000	Year to 28 Feb 07 £'000
Net cash outflow from operating activities	(26)	(85)	(139)
Capital expenditure and financial investment			
Purchase of investments	(13)	(49)	(49)
Disposal of investments	-	-	10
Net cash outflow from capital expenditure and financial investment	(13)	(49)	(39)
Decrease in cash	(39)	(134)	(178)

Company Information

Directors

John Jackson (Chairman)
Richard Vessey
Lucius Cary
Michael O'Regan
Sir Martin Wood

Registrars

Capita Registrars
Northern House
Woodsome Park
Fenay Bridge
Huddersfield
West Yorkshire HD8 0LA

Registered Office

Magdalen Centre
Oxford Science Park
Oxford
OX4 4GA

Investment Manager

Oxford Technology Management
Magdalen Centre
Oxford Science Park
Oxford
OX4 4GA

Secretary

James Gordon


Brokers

JP Morgan Cazenove
20 Moorgate
London EC2R 6DA

Notes to the Unaudited Financial Information on pages 2 and 3

- 1 The financial information for each of the interim periods ended 31 August 2007 and 31 August 2006 is unaudited and does not constitute statutory accounts within the meaning of the Companies Act 1985. It has been prepared using accounting policies consistent with those set out in the company's statutory accounts for the year ending 28 February 2007. The financial information for the year ended 28 February 2007 has been extracted from the company's statutory accounts for that period which contained an unqualified audit report and which have been filed with the Registrar of Companies.
- 2 The calculation of earnings per share for the period is based on the return attributable to shareholders divided by the weighted average number of shares in issue during the period.
- 3 Listed investments are stated at market value based upon middle market prices at the accounting period end. The unrealised depreciation or appreciation on the valuation of investments and the gains and losses arising on the disposal of investments are dealt with in the capital reserve.
- 4 Copies of the Interim Statement are being sent to shareholders and further copies can be obtained from the Company's Registered Office.

Oxford Technology 3 Venture Capital Trust plc



Interim Statement

**For the period
1 March 2007 to 31 August 2007**